Trial Profile
A Multicenter, Open Label, Single Arm, Phase II Study to Investigate the Efficacy and Safety of Sorafenib (Nexavar) in Combination With Gemcitabine in Patients With Advanced Hepatocellular Carcinoma (HCC).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Aug 2011
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 26 Aug 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 17 Jul 2008 New trial record.